Nascent Biotech, Inc. (NBIO) Stock Price & Analysis
Nascent Biotech, Inc. (NBIO) — price $0.0001 (-75.00%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Nascent Biotech, Inc. · NBIO
Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody treatments for various cancers, including glioblastoma, with its lead candidate Pritumumab. The company is also advancing its proprietary MultiPharm technology platform for broader therapeutic applications in cancer, diabetes, autoimmune disorders, and transplantation.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.0001 |
| Change on the day | -75.00% |
| Shares traded on the day | 15.0K |
Price & events
Other perspectives
Council score for Nascent Biotech (NBIO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Nascent Biotech (NBIO), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Nascent Biotech, Inc. (NBIO) is the company analyzed here. In Q4 FY2024 it reported revenue of $3.376 and net income of -$513,000.
What do the latest results show for Nascent Biotech (NBIO)?
Short answer · as of
The most recent reported quarter, Q4 FY2024, carried revenue of $3.376.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2024 | $3.376 | -$513,000 | -$0.0030 (diluted) |
What are the financial strengths and risks for Nascent Biotech (NBIO)?
Short answer · as of
The distress and quality screens read Piotroski F 1. Trailing ratios: ROE 268.9% · current ratio 0.68.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held NBIO in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported NBIO in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About NBIO
These answers are editorial: 1 of these 1 answer is drawn from the NBIO research dossier (written Jun 14, 2026 by gemini-2.5-flash). Figures in this section are not part of the source register.
What is the potential of Nascent Biotech, Inc.'s MultiPharm technology platform?
Nascent Biotech, Inc.'s MultiPharm technology platform represents a significant potential growth driver beyond its lead candidate, Pritumumab. This proprietary platform is being developed with broad therapeutic applicability across several high-need medical areas.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 9 figures on this page — 7 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com